PL4034115T3 - Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina - Google Patents

Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina

Info

Publication number
PL4034115T3
PL4034115T3 PL20868013.2T PL20868013T PL4034115T3 PL 4034115 T3 PL4034115 T3 PL 4034115T3 PL 20868013 T PL20868013 T PL 20868013T PL 4034115 T3 PL4034115 T3 PL 4034115T3
Authority
PL
Poland
Prior art keywords
tetrahydroisoquinoline
conjugate
pharmaceutical composition
thrombolytic peptide
thrombolytic
Prior art date
Application number
PL20868013.2T
Other languages
English (en)
Inventor
David Chih-Kuang Chou
Original Assignee
Lumosa Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumosa Therapeutics Co., Ltd. filed Critical Lumosa Therapeutics Co., Ltd.
Publication of PL4034115T3 publication Critical patent/PL4034115T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20868013.2T 2019-09-25 2020-09-24 Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina PL4034115T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905679P 2019-09-25 2019-09-25
PCT/US2020/052514 WO2021062003A1 (en) 2019-09-25 2020-09-24 Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate

Publications (1)

Publication Number Publication Date
PL4034115T3 true PL4034115T3 (pl) 2025-05-19

Family

ID=74880327

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20868013.2T PL4034115T3 (pl) 2019-09-25 2020-09-24 Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina

Country Status (24)

Country Link
US (4) US11338008B2 (pl)
EP (2) EP4516288A3 (pl)
JP (1) JP7649300B2 (pl)
KR (1) KR102706799B1 (pl)
CN (2) CN119838019A (pl)
AU (1) AU2020353076B2 (pl)
CA (1) CA3154762C (pl)
DK (1) DK4034115T3 (pl)
ES (1) ES3017234T3 (pl)
FI (1) FI4034115T3 (pl)
HR (1) HRP20250453T1 (pl)
HU (1) HUE070923T2 (pl)
IL (1) IL291380B2 (pl)
LT (1) LT4034115T (pl)
MX (1) MX2022003235A (pl)
MY (1) MY206671A (pl)
PL (1) PL4034115T3 (pl)
PT (1) PT4034115T (pl)
RS (1) RS66705B1 (pl)
SI (1) SI4034115T1 (pl)
SM (1) SMT202500115T1 (pl)
TW (1) TWI838584B (pl)
WO (1) WO2021062003A1 (pl)
ZA (1) ZA202203140B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4034115T (pt) * 2019-09-25 2025-03-25 Lumosa Therapeutics Co Ltd Composição farmacêutica compreendendo conjugado péptido trombolítico-tetra-hidroisoquinolina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785444B2 (en) * 2000-05-19 2007-06-14 Jefferson Pharmaceuticals, Llc Peptide pharmaceutical formulations
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN103665107B (zh) * 2012-09-05 2017-07-14 上海晟顺生物科技有限公司 同时具溶血栓、清除自由基和血栓靶向功能的新颖化合物及其制备方法和用途
EP3006454B1 (en) * 2013-06-05 2021-01-13 Shanghai Lumosa Therapeutics Co., Ltd. New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
PT4034115T (pt) * 2019-09-25 2025-03-25 Lumosa Therapeutics Co Ltd Composição farmacêutica compreendendo conjugado péptido trombolítico-tetra-hidroisoquinolina

Also Published As

Publication number Publication date
EP4516288A3 (en) 2025-06-18
HRP20250453T1 (hr) 2025-06-06
MX2022003235A (es) 2022-04-26
RS66705B1 (sr) 2025-05-30
US20250186534A1 (en) 2025-06-12
PT4034115T (pt) 2025-03-25
MY206671A (en) 2024-12-31
CA3154762A1 (en) 2021-04-01
JP2022549786A (ja) 2022-11-29
TW202126634A (zh) 2021-07-16
JP7649300B2 (ja) 2025-03-19
CN119838019A (zh) 2025-04-18
IL291380A (en) 2022-05-01
HUE070923T2 (hu) 2025-07-28
TWI838584B (zh) 2024-04-11
EP4034115A4 (en) 2023-12-06
US20240024407A1 (en) 2024-01-25
CN114555085A (zh) 2022-05-27
US12059448B2 (en) 2024-08-13
US20210085747A1 (en) 2021-03-25
BR112022005327A2 (pt) 2022-06-14
SMT202500115T1 (it) 2025-05-12
FI4034115T3 (fi) 2025-05-05
AU2020353076B2 (en) 2024-04-18
CN114555085B (zh) 2024-12-27
EP4034115A1 (en) 2022-08-03
US11338008B2 (en) 2022-05-24
EP4516288A2 (en) 2025-03-05
KR102706799B1 (ko) 2024-09-19
AU2020353076A1 (en) 2022-04-07
ES3017234T3 (en) 2025-05-12
IL291380B1 (en) 2025-03-01
EP4034115B1 (en) 2025-01-29
LT4034115T (lt) 2025-04-10
WO2021062003A1 (en) 2021-04-01
IL291380B2 (en) 2025-07-01
US11707501B2 (en) 2023-07-25
NZ786206A (en) 2024-09-27
DK4034115T3 (da) 2025-03-24
US20220370542A1 (en) 2022-11-24
ZA202203140B (en) 2023-12-20
KR20220068998A (ko) 2022-05-26
SI4034115T1 (sl) 2025-04-30
CA3154762C (en) 2024-06-11

Similar Documents

Publication Publication Date Title
DK4015003T3 (da) Forbedret antistof-oligonukleotid-konjugat
EP3946460A4 (en) IMPROVED CONJUGATIONAL LINKERS
DK3794042T5 (da) Anti-muc1-exatecet-antistof-lægemiddelkonjugat
EP4061425A4 (en) DIRECTED CONJUGATION TECHNOLOGIES
IL291486A (en) Therapeutic conjugates
IL285674A (en) Pharmaceutical formulations
DK3897589T3 (da) Farmaceutiske formuleringer indeholdende relacorilant, en heteroaryl-ketonkondenseret azadecalinforbindelse
IL292766A (en) Antibody-drug conjugates targeting claudin 18.2
CL2019003599S1 (es) Extintor.
IL283900A (en) Pharmaceutical combinations
EP3986939A4 (en) TWO-DRUG ANTIBODY-DRUG CONJUGATE
DK3908321T3 (da) Farmaceutisk sammensætning
EP3620471A4 (en) ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE
CL2020001658S1 (es) Empaque.
PL4034115T3 (pl) Kompozycja farmaceutyczna zawierająca koniugat peptyd trombolityczny-tetrahydroizochinolina
PT3949952T (pt) Composição farmacêutica
EP3715533C0 (de) Schachtanordnung
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
PT3996688T (pt) Preparação farmacêutica
EP4032535A4 (en) PHARMACEUTICAL COMPOSITION
IT201900023058A1 (it) Tappo modulare.
EP4081251A4 (en) PHARMACEUTICAL COMPOSITIONS
EP3964264A4 (en) Novel pharmaceutical composition
CL2020000451S1 (es) Cápsula.
CL2020001673S1 (es) Máquina de juegos.